The Antibody Society's Therapeutic Antibody Database (search result 6) and DOTAD (Database of Therapeutic Antibody Developability, search result 7) contain no entries for "DHAD Antibody" among ~5,400+ documented therapeutic antibodies.
Structural Antibody Database (SAbDab) and Observed Antibody Space (OAS) (search results 10, 12) similarly lack records for this designation.
The search results extensively cover:
Anti-D antibodies for RhD prophylaxis (search results 1–5, 8).
CD38-targeting antibodies (e.g., daratumumab) in renal disease (search result 8).
Anti-drug antibodies and their immunogenicity mechanisms (search result 3).
No studies mention "DHAD" as a target antigen, epitope, or clinical candidate.
Nomenclature Error: "DHAD" may represent a typographical error (e.g., "DHA" or "HDAD") or an unofficial abbreviation.
Emerging Research: The compound might be in early preclinical development and not yet published or cataloged.
Proprietary Restrictions: Confidential industry projects may not appear in public databases.
To resolve this discrepancy:
Verify the correct spelling or full name of "DHAD."
Consult proprietary databases (e.g., TABS Therapeutic Antibody Database, search result 9) or patent filings.
Explore niche metabolic pathways (e.g., dihydroxyacid dehydrogenase, an enzyme occasionally abbreviated as DHAD in biochemical contexts) for potential antibody linkages.